NEW ORLEANS, LA – We are proud to recognize Dr. Caroline Campion and the exceptional research team in New Orleans for achieving a remarkable series of milestones in a Phase 3 clinical trial for Social Anxiety Disorder (SAD).

Through seamless coordination, strong patient engagement, and precise operational execution, the site achieved first activation, first patient screened, and first patient enrolled, establishing the pace for the study as a whole.

These early achievements reflect both the expertise of the investigative team and the value of DelRicht’s community-embedded research model, which empowers physicians to deliver high-quality research within their active clinical practices.

The Significance of Advancing Social Anxiety Disorder Research

Social Anxiety Disorder is among the most common mental health conditions in the United States, affecting millions of adolescents and adults each year. Characterized by an intense fear of social or performance situations, SAD can severely impact quality of life, disrupting school, work, relationships, and daily interactions. Despite available therapies, many individuals experience only partial relief or discontinue treatment due to side effects, limited access, or lack of response.

Because of these gaps, new therapeutic options are urgently needed. Late-phase clinical trials, particularly Phase 3 programs, play a crucial role in confirming the safety and efficacy of emerging treatments before they can be made widely available. Accelerating these trials, without compromising patient safety or data quality, is key to ensuring new interventions reach patients faster.

Early site activation and immediate enrollment are among the clearest indicators of strong operational readiness. Achievements like first-to-activate and first-to-enroll not only signal efficiency, but also help set the tone and pace for the entire study, allowing sponsors and CROs to move forward with confidence.

Leaders in Operational Excellence: The New Orleans Team

Dr. Caroline Campion, a board-certified child and adolescent psychiatrist, has been a trusted research partner with DelRicht Research since 2021. Over the past four years, she has contributed to clinical trials across multiple therapeutic areas, consistently demonstrating a commitment to evidence-based care and to expanding research access within her community.

Her clinical insight, steady leadership, and patient-centered approach have made her New Orleans site a model for high-quality research execution. Whether supporting complex inclusion criteria or navigating sensitive mental health assessments, Dr. Campion’s team approaches each study with both precision and empathy.

At the operational helm is Site Manager Morgan Couvillion, whose coordination, attention to detail, and proactive planning were instrumental in achieving this suite of global firsts. Morgan’s ability to mobilize staff, streamline communication, and ensure readiness across all phases of start-up enabled the team to hit the ground running on day one.

Together, Dr. Campion, Morgan, and the broader New Orleans staff embody the excellence that DelRicht Research strives to deliver across every site in our network.

Momentum That Drives Meaningful Impact

Achieving first activation, first patient screened, and first patient enrolled is more than an operational accomplishment, it represents momentum that directly benefits study timelines, participant access, and ultimately, patient outcomes. Faster activation means faster data. Faster data means faster innovation. And faster innovation means patients living with Social Anxiety Disorder may soon have greater hope for relief.

Sponsors and CROs rely on high-performing sites to generate early traction and ensure study success. DelRicht’s New Orleans team has not only met that expectation, they have set a new standard of excellence for others to follow.

At DelRicht Research, we are honored to work alongside investigators like Dr. Campion whose commitment, expertise, and compassion strengthen our mission of Moving Medicine Forward. Their achievements help bring tomorrow’s therapies to today’s patients, and we are grateful for their partnership in driving progress for individuals living with social anxiety disorder.